Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34

1.

Homologous Recombination Deficiency and Platinum-Based Therapy Outcomes in Advanced Breast Cancer.

Zhao EY, Shen Y, Pleasance E, Kasaian K, Leelakumari S, Jones M, Bose P, Ch'ng C, Reisle C, Eirew P, Corbett R, Mungall KL, Thiessen N, Ma Y, Schein JE, Mungall AJ, Zhao Y, Moore RA, Den Brok W, Wilson S, Villa D, Shenkier T, Lohrisch C, Chia S, Yip S, Gelmon K, Lim H, Renouf D, Sun S, Schrader KA, Young S, Bosdet I, Karsan A, Laskin J, Marra MA, Jones SJM.

Clin Cancer Res. 2017 Dec 15;23(24):7521-7530. doi: 10.1158/1078-0432.CCR-17-1941.

PMID:
29246904
2.

Willingness of breast cancer patients to undergo biopsy and breast cancer clinicians' practices around seeking biopsy at the time of breast cancer relapse.

Lohrisch C, Francl M, Sun S, Villa D, Gelmon KA.

Breast Cancer Res Treat. 2018 Feb;168(1):221-228. doi: 10.1007/s10549-017-4586-9. Epub 2017 Nov 27.

PMID:
29181718
3.

Lifetime moderate-to-vigorous physical activity and ER/PR/HER-defined post-menopausal breast cancer risk.

Shi J, Kobayashi LC, Grundy A, Richardson H, SenGupta SK, Lohrisch CA, Spinelli JJ, Aronson KJ.

Breast Cancer Res Treat. 2017 Aug;165(1):201-213. doi: 10.1007/s10549-017-4323-4. Epub 2017 Jun 6.

PMID:
28589367
4.

A phase-I study of lapatinib in combination with foretinib, a c-MET, AXL and vascular endothelial growth factor receptor inhibitor, in human epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancer.

Chia SK, Ellard SL, Mates M, Welch S, Mihalcioiu C, Miller WH Jr, Gelmon K, Lohrisch C, Kumar V, Taylor S, Hagerman L, Goodwin R, Wang T, Sakashita S, Tsao MS, Eisenhauer E, Bradbury P.

Breast Cancer Res. 2017 May 2;19(1):54. doi: 10.1186/s13058-017-0836-3.

5.

Response to "Do metastasis-free interval less or more than 24 months for recurrent metastatic breast cancer and primary surgery for de novo metastatic breast cancer matter for survival?"

den Brok WD, Speers CH, Gondara L, Baxter E, Tyldesley SK, Lohrisch CA.

Breast Cancer Res Treat. 2017 Apr;162(2):397-398. doi: 10.1007/s10549-017-4114-y. No abstract available.

PMID:
28110478
6.

Survival with metastatic breast cancer based on initial presentation, de novo versus relapsed.

den Brok WD, Speers CH, Gondara L, Baxter E, Tyldesley SK, Lohrisch CA.

Breast Cancer Res Treat. 2017 Feb;161(3):549-556. doi: 10.1007/s10549-016-4080-9. Epub 2016 Dec 20.

PMID:
28000014
7.

Polymorphisms of Insulin-Like Growth Factor 1 Pathway Genes and Breast Cancer Risk.

Shi J, Aronson KJ, Grundy A, Kobayashi LC, Burstyn I, Schuetz JM, Lohrisch CA, SenGupta SK, Lai AS, Brooks-Wilson A, Spinelli JJ, Richardson H.

Front Oncol. 2016 Jun 8;6:136. doi: 10.3389/fonc.2016.00136. eCollection 2016.

8.

Risk of Recurrence or Contralateral Breast Cancer More than 5 Years After Diagnosis of Hormone Receptor-Positive Early-Stage Breast Cancer.

Wilson S, Speers C, Tyldesley S, Chia S, Kennecke H, Ellard S, Lohrisch C.

Clin Breast Cancer. 2016 Aug;16(4):284-90. doi: 10.1016/j.clbc.2015.11.002. Epub 2015 Nov 17.

PMID:
26705158
9.

Genetic variation in vitamin D-related genes and risk of breast cancer among women of European and East Asian descent.

Shi J, Grundy A, Richardson H, Burstyn I, Schuetz JM, Lohrisch CA, SenGupta SK, Lai AS, Brooks-Wilson A, Spinelli JJ, Aronson KJ.

Tumour Biol. 2016 May;37(5):6379-87. doi: 10.1007/s13277-015-4417-8. Epub 2015 Dec 2.

PMID:
26631034
10.

Using proliferative markers and Oncotype DX in therapeutic decision-making for breast cancer: the B.C. experience.

Baxter E, Gondara L, Lohrisch C, Chia S, Gelmon K, Hayes M, Davidson A, Tyldesley S.

Curr Oncol. 2015 Jun;22(3):192-8. doi: 10.3747/co.22.2284.

11.

Comparison of toxicity experienced by older versus younger patients enrolled in breast cancer clinical trials.

Mariano C, Francl M, Pope J, Wong L, Lim HJ, Lohrisch C.

Clin Breast Cancer. 2015 Feb;15(1):73-9. doi: 10.1016/j.clbc.2014.09.002. Epub 2014 Sep 28.

PMID:
25445420
12.

Increased risk of breast cancer associated with long-term shift work in Canada.

Grundy A, Richardson H, Burstyn I, Lohrisch C, SenGupta SK, Lai AS, Lee D, Spinelli JJ, Aronson KJ.

Occup Environ Med. 2013 Dec;70(12):831-8. doi: 10.1136/oemed-2013-101482. Epub 2013 Jul 1.

PMID:
23817841
13.

A prospective clinical utility and pharmacoeconomic study of the impact of the 21-gene Recurrence Score® assay in oestrogen receptor positive node negative breast cancer.

Davidson JA, Cromwell I, Ellard SL, Lohrisch C, Gelmon KA, Shenkier T, Villa D, Lim H, Sun S, Taylor S, Taylor M, Czerkawski B, Hayes M, Ionescu DN, Yoshizawa C, Chao C, Peacock S, Chia SK.

Eur J Cancer. 2013 Jul;49(11):2469-75. doi: 10.1016/j.ejca.2013.03.009. Epub 2013 Apr 20.

PMID:
23611660
14.

Assessing the real-world cost-effectiveness of adjuvant trastuzumab in HER-2/neu positive breast cancer.

Hedden L, O'Reilly S, Lohrisch C, Chia S, Speers C, Kovacic L, Taylor S, Peacock S.

Oncologist. 2012;17(2):164-71. doi: 10.1634/theoncologist.2011-0379. Epub 2012 Feb 2.

15.

Impact on survival of time from definitive surgery to initiation of adjuvant chemotherapy for early-stage breast cancer.

Lohrisch C, Paltiel C, Gelmon K, Speers C, Taylor S, Barnett J, Olivotto IA.

J Clin Oncol. 2006 Oct 20;24(30):4888-94. Epub 2006 Oct 2.

PMID:
17015884
16.

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Láng I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Rüschoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci MS, Gelber RD; Herceptin Adjuvant (HERA) Trial Study Team.

N Engl J Med. 2005 Oct 20;353(16):1659-72.

18.

Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer.

Paridaens R, Dirix L, Lohrisch C, Beex L, Nooij M, Cameron D, Biganzoli L, Cufer T, Duchateau L, Hamilton A, Lobelle JP, Piccart M; European Organization for the Research and Treatment of Cancer (EORTC)- Investigational Drug Branch for Breast Cancer (IDBBC).

Ann Oncol. 2003 Sep;14(9):1391-8.

PMID:
12954578
19.

Landmark adjuvant randomized clinical trials of systemic therapy in early breast cancer.

Cardoso F, Lohrisch C, Piccart MJ.

Drugs Today (Barc). 2003 Jun;39(6):399-414. Review.

PMID:
12944994
20.

Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III Trial.

Biganzoli L, Cufer T, Bruning P, Coleman R, Duchateau L, Calvert AH, Gamucci T, Twelves C, Fargeot P, Epelbaum R, Lohrisch C, Piccart MJ.

J Clin Oncol. 2002 Jul 15;20(14):3114-21.

PMID:
12118025
21.

Promising results with exemestane in the first-line treatment of metastatic breast cancer: a randomized phase II EORTC trial with a tamoxifen control.

Paridaens R, Dirix L, Beex L, Nooij M, Cufer T, Lohrisch C, Biganzoli L, Van Hoorebeeck I, Duchateau L, Lobelle JP, Piccart M.

Clin Breast Cancer. 2000 Sep;1 Suppl 1:S19-21.

PMID:
11970745
22.
23.

HER2/neu as a predictive factor in breast cancer.

Lohrisch C, Piccart M.

Clin Breast Cancer. 2001 Jul;2(2):129-35; discussion 136-7. Review.

PMID:
11899784
24.

Standard medical treatment for early breast cancer.

Lohrisch C, Piccart MJ.

Eur J Cancer. 2001 Oct;37 Suppl 7:S45-58. Review. No abstract available.

PMID:
11888004
25.

Second and subsequent lines of chemotherapy for metastatic breast cancer: what did we learn in the last two decades?

Cardoso F, Di LA, Lohrisch C, Bernard C, Ferreira F, Piccart MJ.

Ann Oncol. 2002 Feb;13(2):197-207.

PMID:
11885995
26.

An overview of HER2.

Lohrisch C, Piccart M.

Semin Oncol. 2001 Dec;28(6 Suppl 18):3-11. Review.

PMID:
11774200
27.

Taxanes in the adjuvant treatment of breast cancer: why not yet?

Piccart MJ, Lohrisch C, Duchateau L, Buyse M.

J Natl Cancer Inst Monogr. 2001;(30):88-95.

PMID:
11773299
28.

The predictive value of HER2 in breast cancer.

Piccart M, Lohrisch C, Di Leo A, Larsimont D.

Oncology. 2001;61 Suppl 2:73-82. Review.

PMID:
11694791
29.

Near haploid blast phase in a chronic myeloid leukemia detected by fluorescence in situ hybridization using a BCR-ABL probe.

Gancberg D, Dargent JL, Verhest A, Kentos A, Feremans W, Lohrisch C, Kornreich A.

Cancer Genet Cytogenet. 2001 Jul 15;128(2):172-4. No abstract available.

PMID:
11478300
30.

Do we have good surrogate endpoints for survival in breast cancer studies?

Lohrisch C, Piccart MJ.

Tumori. 2000 Sep-Oct;86(5 Suppl 1):S4-10. Review. No abstract available.

PMID:
11195293
31.

Breast cancer: new aspects of adjuvant hormonal therapy.

Lohrisch C, Piccart M.

Ann Oncol. 2000;11 Suppl 3:13-25. Review. No abstract available.

PMID:
11079114
32.
33.

Relationship between tumor location and relapse in 6,781 women with early invasive breast cancer.

Lohrisch C, Jackson J, Jones A, Mates D, Olivotto IA.

J Clin Oncol. 2000 Aug;18(15):2828-35.

PMID:
10920130
34.

Small cell carcinoma of the bladder: long term outcome with integrated chemoradiation.

Lohrisch C, Murray N, Pickles T, Sullivan L.

Cancer. 1999 Dec 1;86(11):2346-52.

PMID:
10590377

Supplemental Content

Loading ...
Support Center